YUNHUI HU

Dr. YUNHUI HU


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2022 in Frontiers in Neuroscience
Verified
Journal Article
Open access
EYErnesto Yagüe
Ernesto Yagüe
HShe sun
he sun
YHYUNHUI HU
YUNHUI HU
Traditional Chinese medicine (TCM) has used herbal remedies for more than 2,000 years. The use of complimentary therapies has increased dramatically during the last years, especially in the West, and the incorporation and modernization of TCM in current medical practice is gaining momentum. We reflect on the main bottlenecks in the modernization of arcane Chinese herbal medicine: lack of standardization, safety concerns and poor quality of clinical trials, as well as the ways these are being overcome. Progress in these areas will facilitate the implementation of an efficacy approach, in which only successful clinical trials lead to the molecular characterization of active compounds and their mechanism of action. Traditional pharmacological methodologies will produce novel leads and drugs, and we describe TCM successes such as the discovery of artemisinin as well as many others still in the pipeline. Neurodegenerative diseases, such as Parkinson’s and Alzheimer’s disease, cancer and cardiovascular disease are the main cause of mortality in the Western world and, with an increasing old population in South East Asia, this trend will also increase in the Far East. TCM has been used for long time for treating these diseases in China and other East Asian countries. However, the holistic nature of TCM requires a paradigm shift. By changing our way of thinking, from “one-target, one-drug” to “network-target, multiple-component-therapeutics,” network pharmacology, together with other system biology methodologies, will pave the way toward TCM modernization.

1 January 2021 in Pharmaceutical Biology
Verified
Journal Article
Open access
YHYUNHUI HU
YUNHUI HU
JSJia Sun
Jia Sun
TWTongxing Wang
Tongxing Wang
HWHairong Wang
Hairong Wang
CZChunlai Zhao
Chunlai Zhao
HShe sun
he sun
Previous studies indicate that compound Danshen Dripping Pill (CDDP) improves the adaptation to high-altitude exposure. However, its mechanism of action is not clear.To explore the protective effec...

1 June 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
KFKe Feng
Ke Feng
YLYuxin Liu
Yuxin Liu
JSJia Sun
Jia Sun
CZChunlai Zhao
Chunlai Zhao
YDYajun Duan
Yajun Duan
Jihong HanJihong Han
Jihong Han
Heart failure (HF) is the advanced heart disease with high morbidity and mortality. Compound DanShen Dripping Pill (CDDP) is a widely used Traditional Chinese Medicine for cardiovascular disease treatment. Herein, we investigated if CDDP can protect mice against doxorubicin (DOX) or isoprenaline (ISO)-induced HF. After 3 days feeding of normal chow containing CDDP, mice were started DOX or ISO treatment for 4 weeks or 18 days. At the end of treatment, mice were conducted electrocardiogram and echocardiographic test. Blood and heart samples were determined biochemical parameters, myocardial structure and expression of the related molecules. CDDP normalized DOX/ISO-induced heart weight changes, HF parameters and fibrogenesis. The DOX/ISO-impaired left ventricular ejection fraction and fractional shortening were restored by CDDP. Mechanistically, CDDP blocked DOX/ISO-inhibited expression of antioxidant enzymes and DOX/ISO-induced expression of pro-fibrotic molecules, inflammation and cell apoptosis. Additional DOX/ISO-impaired targets in cardiac function but protected by CDDP were identified by RNAseq, qRT-PCR and Western blot. In addition, CDDP protected cardiomyocytes against oxygen-glucose deprivation-induced injuries. Taken together, our study shows that CDDP can protect against myocardial injuries in different models, suggesting its potential application for HF treatment.

1 June 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YHYuting Huang
Yuting Huang
KZKai Zhang
Kai Zhang
XWXiao Wang
Xiao Wang
KGKaimin Guo
Kaimin Guo
XLXiaoqiang Li
Xiaoqiang Li
GFGuanwei Fan
Guanwei Fan

16 October 2024 in Phytomedicine
Verified
Journal Article
Closed access
XWXue Wang
Xue Wang
JYJinna Yang
Jinna Yang
XZXiaolian Zhang
Xiaolian Zhang
JCJinyong Cai
Jinyong Cai
JZJieqi Zhang
Jieqi Zhang
JFJiansong Fang
Jiansong Fang

22 May 2023 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
MZMengying Zhang
Mengying Zhang
WWWenjia Wang
Wenjia Wang
HSHe Sun
He Sun
JZJingbo Zhai
Jingbo Zhai
YHYUNHUI HU
YUNHUI HU
Background: Long-term use of nitrates for treating stable angina pectoris (SAP) may lead to patients' tolerance to nitrates. As a traditional Chinese medicine, Compound danshen dropping pills (CDDP) is beneficial for patients with SAP. This study aimed to critically assess the efficacy and safety of CDDP vs. nitrates for SAP.Methods: PubMed, Embase, Web of Science, Cochrane library, CNKI, Wanfang Digital Periodicals, and Chinese Science and Technology Periodicals database were searched from inception to April 2023. Randomized controlled trials (RCTs) comparing CDDP with nitrates for SAP were included. The meta-analysis was conducted to estimate the pooled effect.Results: Twenty-nine studies were included for the statistical analysis. The meta-analyses with the random-effect model indicated that CDDP could significantly increase the effective rate in symptom improvement compared with nitrates (Pooled 9 RCTs, OR = 1.95, 95% CI: 1.25–3.05, P = 0.003, duration of 4 weeks; Pooled 4 RCTs, OR = 3.45, 95% CI: 1.84–6.48, P = 0.0001, duration of 6 weeks; Pooled 13 RCTs, OR = 4.02, 95% CI: 2.14–7.57, P < 0.0001, duration of 8 weeks). The meta-analyses with the random-effect model indicated that CDDP could significantly increase the effective rate in electrocardiogram improvement compared with nitrates (Pooled 5 RCTs, OR = 1.60, 95% CI: 1.02–2.52, P = 0.04, duration of 4 weeks; Pooled 3 RCTs, OR = 2.47, 95% CI: 1.60–3.82, P < 0.0001, duration of 6 weeks; Pooled 11 RCTs, OR = 3.43, 95% CI: 2.68–4.38, P < 0.00001, duration of 8 weeks). The incidence of adverse drug reactions in the CDDP group was lower than that in the nitrates group (Pooled 23 RCTs, OR = 0.15, 95% CI: 0.1–0.21, P < 0.00001). The results of the meta-analyses with fixed-effect model were similar with above results. The levels of the evidence ranged from very low to low.Conclusion: The present study suggests that CDDP with the duration of at least 4 weeks can be considered as an alternative to nitrates for treating SAP. However, more high-quality RCTs are still needed to confirm these findings.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022352888, identifier [CRD42022352888].